Progyny, Inc. (NASDAQ:PGNY) Shares Sold by Truist Financial Corp

Truist Financial Corp decreased its position in Progyny, Inc. (NASDAQ:PGNY) by 29.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 64,993 shares of the company’s stock after selling 26,764 shares during the quarter. Truist Financial Corp’s holdings in Progyny were worth $2,416,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. RiverPark Advisors LLC grew its holdings in shares of Progyny by 54.0% during the fourth quarter. RiverPark Advisors LLC now owns 1,067 shares of the company’s stock worth $40,000 after buying an additional 374 shares in the last quarter. Acadian Asset Management LLC acquired a new position in Progyny in the 3rd quarter valued at $53,000. Parkside Financial Bank & Trust raised its holdings in Progyny by 9.3% in the 4th quarter. Parkside Financial Bank & Trust now owns 3,096 shares of the company’s stock valued at $115,000 after acquiring an additional 264 shares during the last quarter. Cetera Trust Company N.A purchased a new position in shares of Progyny during the 4th quarter worth $183,000. Finally, Duality Advisers LP acquired a new stake in shares of Progyny during the third quarter worth $202,000. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Progyny

In other Progyny news, Chairman David J. Schlanger sold 5,826 shares of the company’s stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $37.74, for a total value of $219,873.24. Following the completion of the transaction, the chairman now owns 86,312 shares in the company, valued at approximately $3,257,414.88. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, Chairman David J. Schlanger sold 5,826 shares of the business’s stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $37.74, for a total transaction of $219,873.24. Following the transaction, the chairman now directly owns 86,312 shares of the company’s stock, valued at $3,257,414.88. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman David J. Schlanger sold 2,597 shares of the company’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $37.65, for a total transaction of $97,777.05. Following the completion of the transaction, the chairman now owns 86,312 shares of the company’s stock, valued at $3,249,646.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 102,770 shares of company stock worth $3,853,985. 12.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

PGNY has been the topic of several recent analyst reports. Truist Financial reiterated a “buy” rating and set a $46.00 target price on shares of Progyny in a research report on Wednesday, April 17th. Cantor Fitzgerald reissued an “overweight” rating and issued a $48.00 target price on shares of Progyny in a research report on Wednesday, February 28th. KeyCorp lowered their target price on shares of Progyny from $45.00 to $43.00 and set an “overweight” rating for the company in a report on Wednesday, February 28th. Leerink Partnrs reaffirmed an “outperform” rating on shares of Progyny in a research note on Monday, February 26th. Finally, SVB Leerink assumed coverage on shares of Progyny in a research note on Monday, February 26th. They set an “outperform” rating and a $49.00 price objective for the company. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Progyny has an average rating of “Buy” and a consensus price target of $48.30.

Progyny Trading Down 2.7 %

Shares of PGNY stock opened at $32.16 on Thursday. The company has a market cap of $3.09 billion, a PE ratio of 51.87, a P/E/G ratio of 1.31 and a beta of 1.51. The company’s fifty day simple moving average is $34.75 and its 200-day simple moving average is $35.61. Progyny, Inc. has a 52 week low of $29.44 and a 52 week high of $44.95.

Progyny (NASDAQ:PGNY) last released its quarterly earnings data on Tuesday, February 27th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.09 by $0.04. The company had revenue of $269.94 million for the quarter, compared to analyst estimates of $274.08 million. Progyny had a return on equity of 12.64% and a net margin of 5.70%. The firm’s revenue was up 26.0% compared to the same quarter last year. During the same period last year, the company posted $0.03 earnings per share. Equities research analysts expect that Progyny, Inc. will post 0.7 EPS for the current fiscal year.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.